鉴别胶质母细胞瘤患者放射性炎症相关改变与早期复发:68Ga-PSMA-11 PET/CT与18F-FDOPA PET/CT比较的初步分析
该初步分析纳入9例胶质母细胞瘤随访患者,在12个月随访期内接受MRI检查后转诊行68Ga-PSMA-11与18F-FDOPA PET/CT。5例两种检查结果相关性好,4例结果矛盾,部分因贝伐珠单抗治疗致PSMA PET/CT未检出复发。作者认为68Ga-PSMA-11 PET/CT在鉴别放射性炎症与复发方面有潜在作用,需更有力的前瞻性研究验证。
要点
- 9例胶质母细胞瘤患者中,5例18F-FDOPA与68Ga-PSMA PET/CT结果相关性好。
- 4例结果矛盾,其中部分因既往贝伐珠单抗治疗致PSMA PET/CT未检出复发。
- 作者认为68Ga-PSMA-11 PET/CT病灶-本底比优异,但需前瞻性研究验证。
核心结论
- 尽管存在少数不一致,本研究提示68Ga-PSMA-11 PET/CT在鉴别放射性炎症与复发方面有潜在作用。
- 68Ga-PSMA-11 PET/CT具有优异的病灶-本底比,检查前实施特定方案可减少假阳性和假阴性结果。
- 需要更有力的前瞻性研究来验证本研究结果。
研究设计与样本
- 该初步研究纳入9例接受12个月随访期间行MRI的胶质母细胞瘤患者,转诊行68Ga-PSMA-11与18F-FDOPA PET/CT。
- 计算了SUVmax、病灶-纹状体比、病灶-正常实质比和病灶-唾液腺比。
主要发现
- 5例患者18F-FDOPA与68Ga-PSMA PET/CT结果相关性好。
- 4例患者两种检查结果均符合复发,但PSMA PET/CT显示更清晰。
- 第5例患者检查提示放射性相关改变,PSMA PET/CT较DOPA PET/CT显示相对低摄取,分析更佳。
- 4例结果矛盾:1例因既往贝伐珠单抗治疗致PSMA PET/CT未检出复发;另1例两种检查均符合复发但可疑病灶处摄取不匹配;2例表现不一致。
局限性
- 该研究为初步分析,样本量为9例。
- 需要更有力的前瞻性研究来验证本研究结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE OF THE REPORT: Using morphological and functional imaging to discriminate recurrence from postradiation-related modifications in patients with glioblastomas remains challenging. This pilot study aimed to assess the feasibility of using 68 Ga-prostate-specific membrane antigen (PSMA) 11 PET/CT compared with 18 F-FDOPA PET/CT to detect early recurrence. METHODS: Nine patients followed up for glioblastomas who received MRI during 12 months of follow-up were referred for both 68 Ga-PSMA-11 and 18 F-FDOPA PET/CT. The SUV max , lesion-to-striatum ratio, lesion-to-normal parenchyma ratio, and lesion-to-salivary gland ratio were calculated. RESULTS: Good correlation between 18 F-FDOPA and 68 Ga-PSMA PET/CT findings was seen in 5 patients. In 4 patients, the findings of both examinations were consistent with recurrence but were better visualized with the PSMA PET/CT. Examinations of the fifth patient were suggestive of postradiation-related changes and were better analyzed with the PSMA PET/CT, which displayed relatively low uptake compared with DOPA PET/CT. Conversely, 4 patients showed conflicting results: recurrence was not detected on the PSMA PET/CT because of previously introduced bevacizumab treatment; in another patient, both examinations were consistent with recurrence, but there was an uptake mismatch at the suspected lesion sites, and 2 patients presented with inconsistent findings. CONCLUSIONS: Despite a few discrepancies, this study highlights the potential role of 68 Ga-PSMA-11 PET/CT for discriminating postradiation inflammation from recurrence. 68 Ga-PSMA-11 PET/CT has an excellent lesion-to-background ratio, and false-positive and false-negative results could be minimized through implementing certain protocols before performing the examination. More powerful prospective studies are required to validate our results.
引用
- Moreau A, Khayi F, Maureille A, et al. Discriminating Inflammatory Radiation-Related Changes From Early Recurrence in Patients With Glioblastomas: A Preliminary Analysis of 68 Ga-PSMA-11 PET/CT Compared With 18 F-FDOPA PET/CT. Clin Nucl Med. 2023. PMID: 37276534. doi:10.1097/RLU.0000000000004716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。